AlloVir price target raised to $19 from $16 at SVB Securities

SVB Securities raised the firm’s price target on AlloVir to $19 from $16 and keeps an Outperform rating on the shares after the company presented long-term follow-up data from the Phase 2 study of posoleucel for the prevention of infections from viruses in allogeneic hematopoietic cell transplant, or allo-HSCT, recipients at the European Society for Blood and Marrow Transplantation annual meeting. Based on the "encouraging" long-term follow-up data, the firm increased its view on the odds of success for the program from to 50% from 25%.